 Moderna Inc stock had added almost 6 on Wednesday morning after the biotechnology company reported positive results from a Phase 3 clinical study involving its vaccine targeting respiratory syncytial virus RSV. The company said its vaccine mRNA-1345 was 83.7 effective against at least two symptoms of RSV-associated lower respiratory tract disease in adults aged 60 years and older. 